Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by Johann Wolfgang Goethe University Hospitals.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier:
NCT00365625
First received: August 16, 2006
Last updated: February 1, 2010
Last verified: August 2009

August 16, 2006
February 1, 2010
July 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00365625 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris
Patient Orientated Basic Science Investigation: Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris

The stepwise process of leukocyte extravasation to inflamed tissues depends on the expression of a variety of cytokines and adhesion molecules. Recently much attention has focused on the Junctional Adhesion Molecules (JAM). The three members of this adhesion molecule family, namely, JAM-A, -B and -C, have been shown to govern the last step of leukocyte extravasation (transmigration) - the process of leukocytes passing between endothelial cells. In addition to transmigration, some members of this family seem to support additional steps in the leukocyte extravasation cascade. The investigators recently showed, that antibody-mediated inhibition of JAM-C significantly reduced hapten induced skin inflammation (J Invest Dermatol;125(5):969).

Recent unpublished work from our laboratory showed, that JAM-C expression of lymphocytes can be up-regulated through specific activators. Hence, the investigators hypothesize, that JAM-C expression is elevated in patients with psoriasis. As it is currently not know, which factors may influence the expression of JAM-C, the investigators intend to analyse JAM-C expression on CD3+CD41- cells at several time-points during the treatment of psoriatic patients. Expression of JAM-C will then be correlated to disease activity (PASI).

The stepwise process of leukocyte extravasation to inflamed tissues depends on the expression of a variety of cytokines and adhesion molecules. Recently much attention has focused on the Junctional Adhesion Molecules (JAM). The three members of this adhesion molecule family, namely, JAM-A, -B and -C, have been shown to govern the last step of leukocyte extravasation (transmigration) - the process of leukocytes passing between endothelial cells. In addition to transmigration, some members of this family seem to support additional steps in the leukocyte extravasation cascade. We recently showed, that antibody-mediated inhibition of JAM-C significantly reduced hapten induced skin inflammation (J Invest Dermatol;125(5):969).

Recent unpublished work from our laboratory showed, that JAM-C expression of lymphocytes can be up-regulated through specific activators. Hence, we hypothesize, that JAM-C expression is elevated in patients with psoriasis. As it is currently not know, which factors may influence the expression of JAM-C, we intend to analyse JAM-C expression on CD3+CD41- cells at several time-points during the treatment of psoriatic patients. Expression of JAM-C will then be correlated to disease activity (PASI).

Detailed in- and exclusion criteria are outlined below.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

psoriasis patients

  • Psoriasis
  • Psoriasis Vulgaris
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
December 2007
Not Provided

Inclusion Criteria:

  • Psoriasis vulgaris
  • PASI >/= 10 at inclusion

Exclusion Criteria:

  • Psoriasis arthritis
  • Psoriasis pustulosa
  • Psoriasis palmoplantaris
  • Pregnancy
  • current infectious disease
Both
18 Years and older
No
Contact: Ralf J Ludwig, MD 0049-69-6301- ext 6162 r.ludwig@em.uni-frankfurt.de
Contact: Wolf-Henning Boehncke, Professor 0049-69-6301- ext 5743 boehncke@em.uni-frankfurt.de
Germany
 
NCT00365625
244/06
Not Provided
Prof. Ralf Ludwig, Johann Wolfgang Goethe University Hospitals
Johann Wolfgang Goethe University Hospitals
Not Provided
Principal Investigator: Ralf J Ludwig, MD Department of Dermatology - Clinic of the Johann Wolfgang Goethe University
Study Chair: Roland Kaufmann, Professor Department of Dermatology - Clinic of the Johann Wolfgang Goethe University
Study Chair: Wolf-Henning Boehncke, Professor Department of Dermatology - Clinic of the Johann Wolfgang Goethe University
Johann Wolfgang Goethe University Hospitals
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP